WHO's Who in Breast Cytology: Case-Based Overview of WHO Reporting System for Breast Cytopathology
Tracking # 20-1377824
$99999.00
There are no ratings for this course
Learn moreCourse overview
Breast fine-needle aspiration (FNA) is an inexpensive, minimally-invasive, well-tolerated technique that provides rapid and accurate diagnosis. Over recent years, the number of breast FNA procedures has dramatically decreased in many medically well-resourced countries. This decline is largely due to the rise of popularity of core-needle biopsy, which is perceived to have higher diagnostic accuracy. Breast FNA cytology and core-needle biopsy each provide complementary roles. There is tremendous value in maintaining competency and skill in breast FNAs. The WHO System for Reporting Breast Cytopathology will provide an update to the IAC Yokohama System and will serve as an organized approach to classifying breast FNA samples. This presentation will review the WHO System and apply it to common entities in a case-based approach, including morphologic mimics and immunocytochemical pitfalls. Target Audience This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community. Learning Objectives Appreciate the key cytologic features of common benign and malignant lesions of the breast Interpret immunocytochemical stains in a variety of breast lesions Introduce the WHO International System for Breast Cytopathology classification system Solidify the acquired knowledge through engaging case studies Raza S. Hoda, MD Assistant Professor of Pathology Staff Pathologist Cleveland Clinic Cleveland, Ohio
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Clinical Laboratory Personnel
Clinical Laboratory Director
Clinical Laboratory Supervisor
Clinical Laboratory Technician
Clinical Laboratory Technologist
Public Health Director
Public Health Supervisor
Public Health Technologist
Disclosure statements
The presenter has no conflicts of interest or financial relationships to disclose.